A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Status:
COMPLETED
Trial end date:
2024-11-03
Target enrollment:
Participant gender:
Summary
A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap